This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
documentation:oncology:meeting_notes_2017_oct-19 [2017/10/28 18:07] rimma_belenkaya |
documentation:oncology:meeting_notes_2017_oct-19 [2017/10/30 15:17] (current) rimma_belenkaya |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| {{:documentation:oncology:f-t-f_oncology_meeting.docx|Face-to-Face Oncology Meeting Notes}} | {{:documentation:oncology:f-t-f_oncology_meeting.docx|Face-to-Face Oncology Meeting Notes}} | ||
| - | Next steps | + | **Next steps** |
| - | I. Tasks to generate the minimal viable product | + | **I. Tasks to generate the minimal viable product** |
| 1. Diagnosis | 1. Diagnosis | ||
| Line 23: | Line 23: | ||
| 2. Staging | 2. Staging | ||
| + | |||
| Choose vocabulary | Choose vocabulary | ||
| + | ??? | ||
| 3. Treatments | 3. Treatments | ||
| + | |||
| a. Drugs | a. Drugs | ||
| - | • Compare SEER drugs list with RxNorm cancer drug classes and decide which one should be used in the vocabulary. If SEER is more suitable, add SEER classification to the vocabulary. | + | * Compare SEER drugs list with RxNorm cancer drug classes and decide which one should be used in the vocabulary. If SEER is more suitable, add SEER classification to the vocabulary. |
| - | • Add SEER drug cocktails to the vocabulary (only ingredients, no other specifics) in EMR based on those combinations. | + | * Add SEER drug cocktails to the vocabulary (only ingredients, no other specifics) in EMR based on those combinations. |
| - | • Identify chemo regimens in EMR using SEER cocktails and validate with chemo orders when available | + | * Identify chemo regimens in EMR using SEER cocktails and validate with chemo orders when available |
| - | • Work on cancer Drug Era algorithm and modeling in CDM | + | * Work on cancer Drug Era algorithm and modeling in CDM |
| b. Overlay cancer registry treatment schema (first occurrence only) with EMR details to construct complete treatment regimen | b. Overlay cancer registry treatment schema (first occurrence only) with EMR details to construct complete treatment regimen | ||
| + | |||
| c. Model representation of the treatment regimen (era) in the CDM | c. Model representation of the treatment regimen (era) in the CDM | ||
| - | II. Exploratory | ||
| - | 1. Discuss with IMO procedure mappings to SNOMED and classification of cancer cases. | ||
| - | 2. Explore commercial solutions that claim to identify cancer treatment regimens, recurrences, progression and compare the outcomes with our attempts to identify treatment regimens | ||
| - | 3. Invite Andrew Stewart and Mark Denise to present their efforts and results in mapping to CDM and additional modeling | ||
| - | 4. Find a geneticist and oncologist to identify cancer-relevant genomic areas | ||
| - | 5. Find out if we can get cancer registry data from any of the “SEER” states | ||
| - | III. Operational | + | **II. Exploratory** |
| - | 1. Document challenges related to extending OHDSI infrastructure to support cancer research for NCI | + | - Discuss with IMO procedure mappings to SNOMED and classification of cancer cases. |
| + | - Explore commercial solutions that claim to identify cancer treatment regimens, recurrences, progression and compare the outcomes with our attempts to identify treatment regimens | ||
| + | - Invite Andrew Stewart and Mark Denise to present their efforts and results in mapping to CDM and additional modeling | ||
| + | - Find a geneticist and oncologist to identify cancer-relevant genomic areas | ||
| + | - Find out if we can get cancer registry data from any of the “SEER” states | ||
| + | |||
| + | **III. Operational** | ||
| + | |||
| + | Document challenges related to extending OHDSI infrastructure to support cancer research for NCI | ||